Cancers, Free Full-Text
Descrição
Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers. However, XPO1 biology and selinexor sensitivity in childhood cancer is only recently being explored. In this review, we will focus on the differential biology of childhood and adult cancers as it relates to XPO1 and key cargo proteins. We will further explore the current state of pre-clinical and clinical development of XPO1 inhibitors in childhood cancers. Finally, we will outline potentially promising future therapeutic strategies for, as well as potential challenges to, integrating XPO1 inhibition to improve outcomes for children with cancer.
Destination Healthy Skin Toolkit - The Skin Cancer Foundation
PDF) Discovery and validation of methylation signatures in
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast
Frontiers Cell-Free DNA: Hope and Potential Application in Cancer
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Cancers, Free Full-Text
Loco Evolution Binary Patch - Colaboratory
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C
PDF) Late Stage Cervical Cancer among Confirmed Cervical Cancer
Cancer Innovation - Wiley Online Library
Cancer burden among adolescents and young adults in relation to
International Journal of Cancer - Wiley Online Library
Multimodal analysis of methylomics and fragmentomics in plasma
Cancers, Free Full-Text
Predicting peritoneal recurrence and disease-free survival from CT
de
por adulto (o preço varia de acordo com o tamanho do grupo)
